Latest news with #StepanCompany
Gulf Insider
4 days ago
- Business
- Gulf Insider
How Coca-Cola's Secret Formula Has Changed Over Time
Coca-Cola debuted in 1886 as a pharmacy fountain drink. Its original syrup drew on coca leaves and kola nuts for stimulation and flavor. Over time, the recipe changed alongside regulations, technology, and tastes. In the following chart, Visual Capitalist's Bruno Venditti pairs a quick dataset with context on how ingredients and nutrition have evolved. Early formulas included coca leaf extract, and small amounts of cocaine remained until the early 1900s. By 1903, the drug was removed amid changing laws and public health concerns. Coca-leaf flavoring persisted in 'decocainized' form, prepared under license in the U.S. by a facility now operated by Stepan Company. These shifts preserved the brand's flavor profile while complying with evolving regulation. In the U.S., Coca-Cola transitioned from cane sugar to high-fructose corn syrup (HFCS) during the 1980s, with reporting in 1984 noting the move across major soda brands. Cost and supply dynamics favored corn syrup at the time. Not every market followed: in the U.K., for instance, Coca-Cola Original lists 'sugar' rather than HFCS. This split explains why 'Mexican Coke' tastes different to some consumers. 'I have been speaking to Coca-Cola about using real cane sugar in Coke in the United States, and they have agreed to do so… It's just better!' – Donald Trump U.S. Coke has six standard ingredients: carbonated water, HFCS, caramel color, phosphoric acid, natural flavors, and caffeine. A 20 fl oz (591 mL) bottle has ~240 calories, ~65 g added sugar, and ~75 mg sodium, though labels can vary. Because the 1886 recipe is proprietary and not publicly released, a direct comparison isn't possible. Following Trump's push, Coca-Cola has announced it will launch a new product sweetened with U.S.-produced cane sugar next fall.
Yahoo
15-07-2025
- Business
- Yahoo
Stepan to Announce Second Quarter 2025 Results on July 30, 2025
NORTHBROOK, Ill., July 15, 2025 /PRNewswire/ -- Stepan Company (NYSE: SCL) will issue its second quarter 2025 earnings results on Wednesday, July 30, 2025 at approximately 7:00 a.m. ET (6:00 a.m. CT). Supporting slides will be posted at approximately the same time on the Investors/Presentations page at The Company will hold a conference call to discuss and answer questions about its financial and operational performance on the same day at 9:00 a.m. ET (8:00 a.m. CT). The call will be hosted by Luis E. Rojo, President and Chief Executive Officer, and Ruben Velasquez, Vice President and Chief Financial Officer. The call can be accessed by phone and webcast. To access the call by phone, please click on this Registration Link, complete the form and you will be provided with dial in details and a PIN. To avoid delays, we encourage participants to dial into the conference call ten minutes ahead of the scheduled start time. The webcast can be accessed through the Investors/Conference Calls page at A webcast replay of the conference call will be available at the same location shortly after the call. Corporate Profile Stepan Company is a major manufacturer of specialty and intermediate chemicals used in a broad range of industries. Stepan is a leading merchant producer of surfactants, which are the key ingredients in consumer and industrial cleaning and disinfection products and in agricultural and oilfield solutions. The Company is also a leading supplier of polyurethane polyols used in the expanding thermal insulation market, and CASE (Coatings, Adhesives, Sealants, and Elastomers) industries. Headquartered in Northbrook, Illinois, Stepan utilizes a network of modern production facilities located in North and South America, Europe and Asia. The Company's common stock is traded on the New York Stock Exchange (NYSE) under the symbol SCL. For more information about Stepan Company please visit the Company online at More information about Stepan's sustainability program can be found on the Sustainability page at Certain information in this news release consists of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include statements about Stepan Company's plans, objectives, strategies, financial performance and outlook, trends, the amount and timing of future cash distributions, prospects or future events and involve known and unknown risks that are difficult to predict. As a result, Stepan Company's actual financial results, performance, achievements or prospects may differ materially from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the use of words such as "may," "could," "expect," "intend," "plan," "seek," "anticipate," "believe," "estimate," "guidance," "predict," "potential," "continue," "likely," "will," "would," "should," "illustrative" and variations of these terms and similar expressions, or the negative of these terms or similar expressions. Such forward-looking statements are necessarily based upon estimates and assumptions that, while considered reasonable by Stepan Company and its management based on their knowledge and understanding of the business and industry, are inherently uncertain. These statements are not guarantees of future performance, and stockholders should not place undue reliance on forward-looking statements. There are a number of risks, uncertainties and other important factors, many of which are beyond Stepan Company's control, that could cause actual results to differ materially from the forward-looking statements contained in this news release. Such risks, uncertainties and other important factors include, among other factors, the risks, uncertainties and factors described in Stepan Company's Form 10-K, Form 10-Q and Form 8-K reports and exhibits to those reports, and include (but are not limited to) risks and uncertainties related to accidents, unplanned production shutdowns or disruptions in manufacturing facilities; reduced demand due to customer product reformulations or new technologies; our inability to successfully develop or introduce new products; compliance with laws; our ability to identify suitable acquisition candidates and successfully complete and integrate acquisitions; global competition; volatility of raw material and energy costs and supply; disruptions in transportation or significant changes in transportation costs; downturns in certain industries and general economic downturns; international business risks, including currency exchange rate fluctuations, legal restrictions and taxes; unfavorable resolution of litigation against us; maintaining and protecting intellectual property rights; our ability to access capital markets; global political, military, security or other instability; costs related to expansion or other capital projects; interruption or breaches of information technology systems; our ability to retain executive management and key personnel; and our debt covenants. These forward-looking statements are made only as of the date hereof, and Stepan Company undertakes no obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. View original content to download multimedia: SOURCE Stepan Company Sign in to access your portfolio
Yahoo
12-06-2025
- Business
- Yahoo
Stepan (NYSE:SCL) shareholders have endured a 40% loss from investing in the stock three years ago
In order to justify the effort of selecting individual stocks, it's worth striving to beat the returns from a market index fund. But the risk of stock picking is that you will likely buy under-performing companies. We regret to report that long term Stepan Company (NYSE:SCL) shareholders have had that experience, with the share price dropping 44% in three years, versus a market return of about 64%. And more recent buyers are having a tough time too, with a drop of 34% in the last year. Since shareholders are down over the longer term, lets look at the underlying fundamentals over the that time and see if they've been consistent with returns. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. There is no denying that markets are sometimes efficient, but prices do not always reflect underlying business performance. One way to examine how market sentiment has changed over time is to look at the interaction between a company's share price and its earnings per share (EPS). During the three years that the share price fell, Stepan's earnings per share (EPS) dropped by 26% each year. This fall in the EPS is worse than the 17% compound annual share price fall. This suggests that the market retains some optimism around long term earnings stability, despite past EPS declines. The company's earnings per share (over time) is depicted in the image below (click to see the exact numbers). We like that insiders have been buying shares in the last twelve months. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. This free interactive report on Stepan's earnings, revenue and cash flow is a great place to start, if you want to investigate the stock further. It is important to consider the total shareholder return, as well as the share price return, for any given stock. The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. In the case of Stepan, it has a TSR of -40% for the last 3 years. That exceeds its share price return that we previously mentioned. And there's no prize for guessing that the dividend payments largely explain the divergence! While the broader market gained around 13% in the last year, Stepan shareholders lost 33% (even including dividends). However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 6% over the last half decade. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. It's always interesting to track share price performance over the longer term. But to understand Stepan better, we need to consider many other factors. Consider for instance, the ever-present spectre of investment risk. We've identified 2 warning signs with Stepan (at least 1 which is significant) , and understanding them should be part of your investment process. Stepan is not the only stock that insiders are buying. For those who like to find lesser know companies this free list of growing companies with recent insider purchasing, could be just the ticket. Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Fibre2Fashion
05-06-2025
- Business
- Fibre2Fashion
Stepan expands AOS output across US facilities
Stepan Company a global leader in specialty and intermediate chemicals, announced a significant increase in its production capacity for Alpha Olefin Sulfonates (AOS). Through strategic capital investments and process improvements, Stepan has expanded its AOS capacity by 25%. Stepan Company has increased its Alpha Olefin Sulfonates (AOS) production capacity by 25 per cent through capital investments and process upgrades at facilities in Illinois, California, and Georgia. AOS is a versatile, eco-friendly surfactant used in personal care and industrial products. The expansion boosts efficiency, reliability, and Stepan's ability to meet rising demand. With the broadest network of sites and plants producing AOS in North America, Stepan continues to expand its production capacity through strategic initiatives at its Millsdale, Illinois; Anaheim, California; and Winder, Georgia facilities. These efforts included targeted capital investments and process enhancements that have strengthened operational efficiency across multiple locations—delivering increased capacity, greater flexibility, and enhanced reliability for Stepan's customers. "We are excited to announce these enhancements to our AOS production capabilities," said Brandon Suttle, Asset Manager – Sulfonation BM - Product Management. "These improvements not only increase our capacity but also position us to better serve our customers with high-quality AOS products." Stepan's Alpha Olefin Sulfonates are versatile surfactants used in detergents, personal care products, cleaning and industrial applications. Known for their fat-dissolving power, foam stability, and gentle cleansing properties, AOS is ideal for green bathroom cleaners, daily shower cleaners, liquid dishwashing detergents, shampoos, body washes, and facial cleansers. With the rise in demand for sulfate-free products, AOS is a preferred choice for formulators. It offers environmental benefits and produces dense, stable foam, making it appealing for luxurious lather. AOS is also used in Oilfield, Agriculture, Construction, and Emulsion Polymerization industries. Adriano Galimberti, Vice President & Surfactants North America at Stepan, added, "Our commitment to continued improvement and operational excellence has enabled us to prioritize these investments to meet the growing demands of our customers." Stepan continues to explore additional improvements to further expand capacity, develop specialty AOS products, and enhance product quality. Note: The headline, insights, and image of this press release may have been refined by the Fibre2Fashion staff; the rest of the content remains unchanged. Fibre2Fashion News Desk (HU)
Yahoo
25-04-2025
- Business
- Yahoo
At US$48.61, Is It Time To Put Stepan Company (NYSE:SCL) On Your Watch List?
Stepan Company (NYSE:SCL), might not be a large cap stock, but it saw significant share price movement during recent months on the NYSE, rising to highs of US$65.59 and falling to the lows of US$45.26. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether Stepan's current trading price of US$48.61 reflective of the actual value of the small-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let's take a look at Stepan's outlook and value based on the most recent financial data to see if there are any catalysts for a price change. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. The share price seems sensible at the moment according to our price multiple model, where we compare the company's price-to-earnings ratio to the industry average. In this instance, we've used the price-to-earnings (PE) ratio given that there is not enough information to reliably forecast the stock's cash flows. We find that Stepan's ratio of 21.77x is trading slightly above its industry peers' ratio of 18.19x, which means if you buy Stepan today, you'd be paying a relatively reasonable price for it. And if you believe that Stepan should be trading at this level in the long run, then there should only be a fairly immaterial downside vs other industry peers. Furthermore, Stepan's share price also seems relatively stable compared to the rest of the market, as indicated by its low beta. This may mean it is less likely for the stock to fall lower from natural market volatility, which suggests less opportunities to buy moving forward. Check out our latest analysis for Stepan Future outlook is an important aspect when you're looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Buying a great company with a robust outlook at a cheap price is always a good investment, so let's also take a look at the company's future expectations. Stepan's earnings over the next few years are expected to increase by 97%, indicating a highly optimistic future ahead. This should lead to more robust cash flows, feeding into a higher share value. Are you a shareholder? SCL's optimistic future growth appears to have been factored into the current share price, with shares trading around industry price multiples. However, there are also other important factors which we haven't considered today, such as the financial strength of the company. Have these factors changed since the last time you looked at SCL? Will you have enough confidence to invest in the company should the price drop below the industry PE ratio? Are you a potential investor? If you've been keeping an eye on SCL, now may not be the most optimal time to buy, given it is trading around industry price multiples. However, the optimistic forecast is encouraging for SCL, which means it's worth further examining other factors such as the strength of its balance sheet, in order to take advantage of the next price drop. Keep in mind, when it comes to analysing a stock it's worth noting the risks involved. While conducting our analysis, we found that Stepan has 1 warning sign and it would be unwise to ignore this. If you are no longer interested in Stepan, you can use our free platform to see our list of over 50 other stocks with a high growth potential. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
